Last reviewed · How we verify

NCT06985628: PNEURO

Alleviating Dyspnea With Non-Invasive Neuromodulation

Completed NA Last updated 24 February 2026
What this trial tests

NA trial testing Transcutaneous vagal nerve stimulation (tVNS) in Dyspnea in 8 participants. Completed in 10 December 2025.

Timeline
18 November 2024
Primary endpoint
10 December 2025
10 December 2025

Quick facts

Lead sponsorUniversité de Sherbrooke
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposetreatment
Enrollment8
Start date18 November 2024
Primary completion10 December 2025
Estimated completion10 December 2025
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Université de Sherbrooke — full company profile →

Who can join

Adults 40 to 85, any sex, with Dyspnea or Chronic Obstructive Pulmonary Disease Severe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this feasibility sham-controlled randomized trial is to assess the feasibility of studying non-invasive neuromodulation techniques, specifically transcutaneous vagal nerve stimulation (tVNS) and transcutaneous electrical nerve stimulation (TENS) of the trigeminal nerve to alleviate dyspnea in patients with chronic pulmonary disease. The main question it aims to answer is: Despite challenges in dyspnea generation and measurement, could non-invasive neuromodulation be reliably studied in chronic obstructive pulmonary disease (COPD) with severe dyspnea? Researchers will compare tVNS and trigeminal TENS to a sham (where the device is applied, but without stimulation) in order to see if non-invasive neuromodulation could relieve dyspnea. At the time of rehabilitation pre-assessment, participants routinely undergo a baseline maximal Cardiopulmonary Exercise Testing (CPET) on ergocycle to measure VO2max with repetitive assessments of the Borg scale and continuous monitoring of vital signs (oxygen saturation, heart rate, blood pressure, respiratory rate) throughout the test. Spirometry and symptom questionnaires (CAT score) are also routinely measured. In two dedicated study visits conducted 2 weeks apart from each other, n=8 participants will perform a submaximal constant workrate (CRW) at 80% workload of the VO2 max, either with cervical tVNS (n=4) or trigeminal TENS (n=4). In a cross-over design, both patient groups will undergo sham and active treatment of the neuromodulation technique in a randomly assigned number.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Non-invasive neuromodulation for alleviating dyspnoea: protocol for a feasibility sham-controlled randomised trial.
    St-Pierre J, Mailhot-Larouche S, Garand G, Vézina FA, et al · · 2025 · PMID 40701604 · DOI 10.1136/bmjopen-2025-103891

Verify or expand the search:

Other trials of Transcutaneous vagal nerve stimulation (tVNS)

Trials testing the same drug.

Other recruiting trials for Dyspnea

Currently open trials in the same condition.

Other Université de Sherbrooke trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06985628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing